nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexrazoxane—TOP2A—prostate cancer	0.357	1	CbGaD
Dexrazoxane—TOP2B—Etoposide—prostate cancer	0.243	0.52	CbGbCtD
Dexrazoxane—TOP2A—Mitoxantrone—prostate cancer	0.0784	0.167	CbGbCtD
Dexrazoxane—TOP2A—Epirubicin—prostate cancer	0.0634	0.135	CbGbCtD
Dexrazoxane—TOP2A—Etoposide—prostate cancer	0.0494	0.106	CbGbCtD
Dexrazoxane—TOP2A—Doxorubicin—prostate cancer	0.0337	0.072	CbGbCtD
Dexrazoxane—TOP2B—prostate gland—prostate cancer	0.00338	0.163	CbGeAlD
Dexrazoxane—TOP2B—seminal vesicle—prostate cancer	0.00286	0.138	CbGeAlD
Dexrazoxane—TOP2A—prostate gland—prostate cancer	0.00249	0.12	CbGeAlD
Dexrazoxane—TOP2B—renal system—prostate cancer	0.00231	0.111	CbGeAlD
Dexrazoxane—TOP2B—urethra—prostate cancer	0.00227	0.109	CbGeAlD
Dexrazoxane—TOP2B—bone marrow—prostate cancer	0.00174	0.0839	CbGeAlD
Dexrazoxane—TOP2B—testis—prostate cancer	0.00149	0.0717	CbGeAlD
Dexrazoxane—TOP2A—bone marrow—prostate cancer	0.00128	0.0617	CbGeAlD
Dexrazoxane—TOP2A—testis—prostate cancer	0.0011	0.0527	CbGeAlD
Dexrazoxane—TOP2B—lymph node—prostate cancer	0.00108	0.052	CbGeAlD
Dexrazoxane—TOP2B—Teniposide—Etoposide—prostate cancer	0.000806	0.233	CbGdCrCtD
Dexrazoxane—TOP2A—lymph node—prostate cancer	0.000794	0.0382	CbGeAlD
Dexrazoxane—TOP2A—Docetaxel—Cabazitaxel—prostate cancer	0.000707	0.205	CbGdCrCtD
Dexrazoxane—TOP2A—Paclitaxel—Cabazitaxel—prostate cancer	0.000488	0.141	CbGdCrCtD
Dexrazoxane—TOP2A—Paclitaxel—Docetaxel—prostate cancer	0.000203	0.0587	CbGdCrCtD
Dexrazoxane—TOP2A—Fulvestrant—Estradiol—prostate cancer	0.000148	0.0428	CbGdCrCtD
Dexrazoxane—TOP2A—Podofilox—Etoposide—prostate cancer	0.00013	0.0377	CbGdCrCtD
Dexrazoxane—TOP2A—Teniposide—Etoposide—prostate cancer	0.00013	0.0377	CbGdCrCtD
Dexrazoxane—TOP2A—Levorphanol—Estrone—prostate cancer	0.000129	0.0373	CbGdCrCtD
Dexrazoxane—TOP2A—Levorphanol—Estradiol—prostate cancer	9.77e-05	0.0283	CbGdCrCtD
Dexrazoxane—TOP2A—Methyltestosterone—Ethinyl Estradiol—prostate cancer	8.92e-05	0.0258	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—SERPINB10—prostate cancer	8.48e-05	0.0435	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—RUNX1—prostate cancer	7.86e-05	0.0403	CbGpPWpGaD
Dexrazoxane—TOP2A—Doxorubicin—Epirubicin—prostate cancer	6.79e-05	0.0196	CbGdCrCtD
Dexrazoxane—TOP2A—Daunorubicin—Epirubicin—prostate cancer	6.79e-05	0.0196	CbGdCrCtD
Dexrazoxane—TOP2A—Idarubicin—Epirubicin—prostate cancer	6.79e-05	0.0196	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—WRN—prostate cancer	6.43e-05	0.033	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—AURKA—prostate cancer	6.34e-05	0.0325	CbGpPWpGaD
Dexrazoxane—TOP2A—Epirubicin—Doxorubicin—prostate cancer	6.28e-05	0.0182	CbGdCrCtD
Dexrazoxane—TOP2A—Idarubicin—Doxorubicin—prostate cancer	6.28e-05	0.0182	CbGdCrCtD
Dexrazoxane—TOP2A—Daunorubicin—Doxorubicin—prostate cancer	6.28e-05	0.0182	CbGdCrCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—ZFHX3—prostate cancer	6.17e-05	0.0316	CbGpPWpGaD
Dexrazoxane—TOP2A—Norethindrone—Ethinyl Estradiol—prostate cancer	5.82e-05	0.0168	CbGdCrCtD
Dexrazoxane—Tremor—Capecitabine—prostate cancer	5.68e-05	0.000381	CcSEcCtD
Dexrazoxane—Neutropenia—Epirubicin—prostate cancer	5.67e-05	0.000381	CcSEcCtD
Dexrazoxane—Angiopathy—Prednisone—prostate cancer	5.63e-05	0.000378	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Capecitabine—prostate cancer	5.62e-05	0.000378	CcSEcCtD
Dexrazoxane—Syncope—Docetaxel—prostate cancer	5.61e-05	0.000377	CcSEcCtD
Dexrazoxane—Pruritus—Estradiol—prostate cancer	5.61e-05	0.000377	CcSEcCtD
Dexrazoxane—Dysphagia—Doxorubicin—prostate cancer	5.61e-05	0.000377	CcSEcCtD
Dexrazoxane—Leukopenia—Docetaxel—prostate cancer	5.6e-05	0.000376	CcSEcCtD
Dexrazoxane—Anaemia—Capecitabine—prostate cancer	5.6e-05	0.000376	CcSEcCtD
Dexrazoxane—Loss of consciousness—Docetaxel—prostate cancer	5.5e-05	0.00037	CcSEcCtD
Dexrazoxane—Weight decreased—Epirubicin—prostate cancer	5.48e-05	0.000368	CcSEcCtD
Dexrazoxane—Dyspnoea—Etoposide—prostate cancer	5.48e-05	0.000368	CcSEcCtD
Dexrazoxane—Alopecia—Prednisone—prostate cancer	5.48e-05	0.000368	CcSEcCtD
Dexrazoxane—Malaise—Capecitabine—prostate cancer	5.47e-05	0.000367	CcSEcCtD
Dexrazoxane—Somnolence—Etoposide—prostate cancer	5.47e-05	0.000367	CcSEcCtD
Dexrazoxane—Cough—Docetaxel—prostate cancer	5.46e-05	0.000367	CcSEcCtD
Dexrazoxane—Syncope—Capecitabine—prostate cancer	5.44e-05	0.000365	CcSEcCtD
Dexrazoxane—Pneumonia—Epirubicin—prostate cancer	5.44e-05	0.000365	CcSEcCtD
Dexrazoxane—Mental disorder—Prednisone—prostate cancer	5.43e-05	0.000365	CcSEcCtD
Dexrazoxane—Diarrhoea—Estradiol—prostate cancer	5.43e-05	0.000365	CcSEcCtD
Dexrazoxane—Leukopenia—Capecitabine—prostate cancer	5.43e-05	0.000364	CcSEcCtD
Dexrazoxane—Infestation—Epirubicin—prostate cancer	5.4e-05	0.000363	CcSEcCtD
Dexrazoxane—Infestation NOS—Epirubicin—prostate cancer	5.4e-05	0.000363	CcSEcCtD
Dexrazoxane—Malnutrition—Prednisone—prostate cancer	5.4e-05	0.000363	CcSEcCtD
Dexrazoxane—Erythema—Prednisone—prostate cancer	5.4e-05	0.000363	CcSEcCtD
Dexrazoxane—Decreased appetite—Etoposide—prostate cancer	5.34e-05	0.000359	CcSEcCtD
Dexrazoxane—Myalgia—Docetaxel—prostate cancer	5.33e-05	0.000358	CcSEcCtD
Dexrazoxane—Loss of consciousness—Capecitabine—prostate cancer	5.33e-05	0.000358	CcSEcCtD
Dexrazoxane—Pancytopenia—Doxorubicin—prostate cancer	5.33e-05	0.000358	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Etoposide—prostate cancer	5.31e-05	0.000357	CcSEcCtD
Dexrazoxane—Asthenia—Mitoxantrone—prostate cancer	5.3e-05	0.000356	CcSEcCtD
Dexrazoxane—Fatigue—Etoposide—prostate cancer	5.3e-05	0.000356	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	5.29e-05	0.000356	CcSEcCtD
Dexrazoxane—Cough—Capecitabine—prostate cancer	5.29e-05	0.000355	CcSEcCtD
Dexrazoxane—Stomatitis—Epirubicin—prostate cancer	5.27e-05	0.000354	CcSEcCtD
Dexrazoxane—Pain—Etoposide—prostate cancer	5.26e-05	0.000353	CcSEcCtD
Dexrazoxane—Constipation—Etoposide—prostate cancer	5.26e-05	0.000353	CcSEcCtD
Dexrazoxane—Dizziness—Estradiol—prostate cancer	5.25e-05	0.000352	CcSEcCtD
Dexrazoxane—Neutropenia—Doxorubicin—prostate cancer	5.24e-05	0.000352	CcSEcCtD
Dexrazoxane—Dry mouth—Docetaxel—prostate cancer	5.21e-05	0.00035	CcSEcCtD
Dexrazoxane—Myalgia—Capecitabine—prostate cancer	5.16e-05	0.000347	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	5.13e-05	0.000344	CcSEcCtD
Dexrazoxane—Discomfort—Capecitabine—prostate cancer	5.1e-05	0.000342	CcSEcCtD
Dexrazoxane—Infection—Docetaxel—prostate cancer	5.08e-05	0.000341	CcSEcCtD
Dexrazoxane—Weight decreased—Doxorubicin—prostate cancer	5.07e-05	0.000341	CcSEcCtD
Dexrazoxane—Feeling abnormal—Etoposide—prostate cancer	5.07e-05	0.00034	CcSEcCtD
Dexrazoxane—Diarrhoea—Mitoxantrone—prostate cancer	5.06e-05	0.00034	CcSEcCtD
Dexrazoxane—Dry mouth—Capecitabine—prostate cancer	5.05e-05	0.000339	CcSEcCtD
Dexrazoxane—Vomiting—Estradiol—prostate cancer	5.04e-05	0.000339	CcSEcCtD
Dexrazoxane—Agranulocytosis—Epirubicin—prostate cancer	5.04e-05	0.000339	CcSEcCtD
Dexrazoxane—Pneumonia—Doxorubicin—prostate cancer	5.03e-05	0.000338	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Etoposide—prostate cancer	5.03e-05	0.000338	CcSEcCtD
Dexrazoxane—Shock—Docetaxel—prostate cancer	5.03e-05	0.000338	CcSEcCtD
Dexrazoxane—Nervous system disorder—Docetaxel—prostate cancer	5.01e-05	0.000337	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Prednisone—prostate cancer	5.01e-05	0.000336	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Docetaxel—prostate cancer	5e-05	0.000336	CcSEcCtD
Dexrazoxane—Infestation NOS—Doxorubicin—prostate cancer	5e-05	0.000336	CcSEcCtD
Dexrazoxane—Infestation—Doxorubicin—prostate cancer	5e-05	0.000336	CcSEcCtD
Dexrazoxane—Anaemia—Prednisone—prostate cancer	4.99e-05	0.000335	CcSEcCtD
Dexrazoxane—Headache—Estradiol—prostate cancer	4.97e-05	0.000334	CcSEcCtD
Dexrazoxane—Skin disorder—Docetaxel—prostate cancer	4.96e-05	0.000333	CcSEcCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—IGFBP3—prostate cancer	4.94e-05	0.0253	CbGpPWpGaD
Dexrazoxane—Infection—Capecitabine—prostate cancer	4.91e-05	0.00033	CcSEcCtD
Dexrazoxane—Urticaria—Etoposide—prostate cancer	4.88e-05	0.000328	CcSEcCtD
Dexrazoxane—Haemoglobin—Epirubicin—prostate cancer	4.88e-05	0.000327	CcSEcCtD
Dexrazoxane—Stomatitis—Doxorubicin—prostate cancer	4.87e-05	0.000327	CcSEcCtD
Dexrazoxane—Anorexia—Docetaxel—prostate cancer	4.87e-05	0.000327	CcSEcCtD
Dexrazoxane—Malaise—Prednisone—prostate cancer	4.87e-05	0.000327	CcSEcCtD
Dexrazoxane—Shock—Capecitabine—prostate cancer	4.87e-05	0.000327	CcSEcCtD
Dexrazoxane—Abdominal pain—Etoposide—prostate cancer	4.86e-05	0.000326	CcSEcCtD
Dexrazoxane—Body temperature increased—Etoposide—prostate cancer	4.86e-05	0.000326	CcSEcCtD
Dexrazoxane—Nervous system disorder—Capecitabine—prostate cancer	4.85e-05	0.000326	CcSEcCtD
Dexrazoxane—Haemorrhage—Epirubicin—prostate cancer	4.85e-05	0.000326	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Capecitabine—prostate cancer	4.84e-05	0.000325	CcSEcCtD
Dexrazoxane—Syncope—Prednisone—prostate cancer	4.84e-05	0.000325	CcSEcCtD
Dexrazoxane—Skin disorder—Capecitabine—prostate cancer	4.81e-05	0.000323	CcSEcCtD
Dexrazoxane—Oedema peripheral—Epirubicin—prostate cancer	4.78e-05	0.000321	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Epirubicin—prostate cancer	4.77e-05	0.00032	CcSEcCtD
Dexrazoxane—Loss of consciousness—Prednisone—prostate cancer	4.75e-05	0.000319	CcSEcCtD
Dexrazoxane—Anorexia—Capecitabine—prostate cancer	4.72e-05	0.000317	CcSEcCtD
Dexrazoxane—Nausea—Estradiol—prostate cancer	4.71e-05	0.000317	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—STMN1—prostate cancer	4.71e-05	0.0241	CbGpPWpGaD
Dexrazoxane—Vomiting—Mitoxantrone—prostate cancer	4.7e-05	0.000316	CcSEcCtD
Dexrazoxane—Agranulocytosis—Doxorubicin—prostate cancer	4.67e-05	0.000313	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.66e-05	0.000313	CcSEcCtD
Dexrazoxane—Headache—Mitoxantrone—prostate cancer	4.63e-05	0.000311	CcSEcCtD
Dexrazoxane—TOP2A—Levonorgestrel—Ethinyl Estradiol—prostate cancer	4.63e-05	0.0134	CbGdCrCtD
Dexrazoxane—Insomnia—Docetaxel—prostate cancer	4.62e-05	0.00031	CcSEcCtD
Dexrazoxane—Myalgia—Prednisone—prostate cancer	4.6e-05	0.000309	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.57e-05	0.000307	CcSEcCtD
Dexrazoxane—Dyspnoea—Docetaxel—prostate cancer	4.56e-05	0.000306	CcSEcCtD
Dexrazoxane—Somnolence—Docetaxel—prostate cancer	4.54e-05	0.000305	CcSEcCtD
Dexrazoxane—Discomfort—Prednisone—prostate cancer	4.54e-05	0.000305	CcSEcCtD
Dexrazoxane—Haemoglobin—Doxorubicin—prostate cancer	4.51e-05	0.000303	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.51e-05	0.000303	CcSEcCtD
Dexrazoxane—Cardiac disorder—Epirubicin—prostate cancer	4.5e-05	0.000302	CcSEcCtD
Dexrazoxane—Haemorrhage—Doxorubicin—prostate cancer	4.49e-05	0.000301	CcSEcCtD
Dexrazoxane—Insomnia—Capecitabine—prostate cancer	4.47e-05	0.000301	CcSEcCtD
Dexrazoxane—Decreased appetite—Docetaxel—prostate cancer	4.44e-05	0.000298	CcSEcCtD
Dexrazoxane—Oedema peripheral—Doxorubicin—prostate cancer	4.42e-05	0.000297	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Docetaxel—prostate cancer	4.41e-05	0.000296	CcSEcCtD
Dexrazoxane—Asthenia—Etoposide—prostate cancer	4.41e-05	0.000296	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Doxorubicin—prostate cancer	4.41e-05	0.000296	CcSEcCtD
Dexrazoxane—Dyspnoea—Capecitabine—prostate cancer	4.41e-05	0.000296	CcSEcCtD
Dexrazoxane—Fatigue—Docetaxel—prostate cancer	4.41e-05	0.000296	CcSEcCtD
Dexrazoxane—Angiopathy—Epirubicin—prostate cancer	4.4e-05	0.000296	CcSEcCtD
Dexrazoxane—Nausea—Mitoxantrone—prostate cancer	4.39e-05	0.000295	CcSEcCtD
Dexrazoxane—Infection—Prednisone—prostate cancer	4.38e-05	0.000294	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Epirubicin—prostate cancer	4.37e-05	0.000294	CcSEcCtD
Dexrazoxane—Pain—Docetaxel—prostate cancer	4.37e-05	0.000293	CcSEcCtD
Dexrazoxane—Constipation—Docetaxel—prostate cancer	4.37e-05	0.000293	CcSEcCtD
Dexrazoxane—Pruritus—Etoposide—prostate cancer	4.35e-05	0.000292	CcSEcCtD
Dexrazoxane—Shock—Prednisone—prostate cancer	4.34e-05	0.000291	CcSEcCtD
Dexrazoxane—Nervous system disorder—Prednisone—prostate cancer	4.32e-05	0.00029	CcSEcCtD
Dexrazoxane—Decreased appetite—Capecitabine—prostate cancer	4.3e-05	0.000289	CcSEcCtD
Dexrazoxane—Alopecia—Epirubicin—prostate cancer	4.29e-05	0.000288	CcSEcCtD
Dexrazoxane—Skin disorder—Prednisone—prostate cancer	4.28e-05	0.000287	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Capecitabine—prostate cancer	4.27e-05	0.000287	CcSEcCtD
Dexrazoxane—Fatigue—Capecitabine—prostate cancer	4.27e-05	0.000286	CcSEcCtD
Dexrazoxane—Mental disorder—Epirubicin—prostate cancer	4.25e-05	0.000285	CcSEcCtD
Dexrazoxane—Pain—Capecitabine—prostate cancer	4.23e-05	0.000284	CcSEcCtD
Dexrazoxane—Constipation—Capecitabine—prostate cancer	4.23e-05	0.000284	CcSEcCtD
Dexrazoxane—Erythema—Epirubicin—prostate cancer	4.22e-05	0.000284	CcSEcCtD
Dexrazoxane—Malnutrition—Epirubicin—prostate cancer	4.22e-05	0.000284	CcSEcCtD
Dexrazoxane—Feeling abnormal—Docetaxel—prostate cancer	4.21e-05	0.000283	CcSEcCtD
Dexrazoxane—Diarrhoea—Etoposide—prostate cancer	4.21e-05	0.000283	CcSEcCtD
Dexrazoxane—Anorexia—Prednisone—prostate cancer	4.2e-05	0.000282	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Docetaxel—prostate cancer	4.18e-05	0.000281	CcSEcCtD
Dexrazoxane—Cardiac disorder—Doxorubicin—prostate cancer	4.17e-05	0.00028	CcSEcCtD
Dexrazoxane—Feeling abnormal—Capecitabine—prostate cancer	4.08e-05	0.000274	CcSEcCtD
Dexrazoxane—Angiopathy—Doxorubicin—prostate cancer	4.07e-05	0.000274	CcSEcCtD
Dexrazoxane—Dizziness—Etoposide—prostate cancer	4.07e-05	0.000273	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Capecitabine—prostate cancer	4.05e-05	0.000272	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Doxorubicin—prostate cancer	4.05e-05	0.000272	CcSEcCtD
Dexrazoxane—Abdominal pain—Docetaxel—prostate cancer	4.04e-05	0.000271	CcSEcCtD
Dexrazoxane—Body temperature increased—Docetaxel—prostate cancer	4.04e-05	0.000271	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Prednisone—prostate cancer	4.01e-05	0.00027	CcSEcCtD
Dexrazoxane—Insomnia—Prednisone—prostate cancer	3.99e-05	0.000268	CcSEcCtD
Dexrazoxane—Alopecia—Doxorubicin—prostate cancer	3.97e-05	0.000266	CcSEcCtD
Dexrazoxane—Mental disorder—Doxorubicin—prostate cancer	3.93e-05	0.000264	CcSEcCtD
Dexrazoxane—Urticaria—Capecitabine—prostate cancer	3.93e-05	0.000264	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Epirubicin—prostate cancer	3.92e-05	0.000263	CcSEcCtD
Dexrazoxane—Abdominal pain—Capecitabine—prostate cancer	3.91e-05	0.000263	CcSEcCtD
Dexrazoxane—Body temperature increased—Capecitabine—prostate cancer	3.91e-05	0.000263	CcSEcCtD
Dexrazoxane—Vomiting—Etoposide—prostate cancer	3.91e-05	0.000263	CcSEcCtD
Dexrazoxane—Malnutrition—Doxorubicin—prostate cancer	3.91e-05	0.000262	CcSEcCtD
Dexrazoxane—Erythema—Doxorubicin—prostate cancer	3.91e-05	0.000262	CcSEcCtD
Dexrazoxane—Anaemia—Epirubicin—prostate cancer	3.9e-05	0.000262	CcSEcCtD
Dexrazoxane—Headache—Etoposide—prostate cancer	3.85e-05	0.000259	CcSEcCtD
Dexrazoxane—Decreased appetite—Prednisone—prostate cancer	3.83e-05	0.000257	CcSEcCtD
Dexrazoxane—Malaise—Epirubicin—prostate cancer	3.81e-05	0.000256	CcSEcCtD
Dexrazoxane—Fatigue—Prednisone—prostate cancer	3.8e-05	0.000255	CcSEcCtD
Dexrazoxane—Syncope—Epirubicin—prostate cancer	3.79e-05	0.000254	CcSEcCtD
Dexrazoxane—Leukopenia—Epirubicin—prostate cancer	3.78e-05	0.000254	CcSEcCtD
Dexrazoxane—Constipation—Prednisone—prostate cancer	3.77e-05	0.000253	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—NAGLU—prostate cancer	3.74e-05	0.0192	CbGpPWpGaD
Dexrazoxane—Loss of consciousness—Epirubicin—prostate cancer	3.71e-05	0.000249	CcSEcCtD
Dexrazoxane—Cough—Epirubicin—prostate cancer	3.69e-05	0.000248	CcSEcCtD
Dexrazoxane—Asthenia—Docetaxel—prostate cancer	3.67e-05	0.000246	CcSEcCtD
Dexrazoxane—Nausea—Etoposide—prostate cancer	3.65e-05	0.000245	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—PRKDC—prostate cancer	3.64e-05	0.0187	CbGpPWpGaD
Dexrazoxane—Feeling abnormal—Prednisone—prostate cancer	3.63e-05	0.000244	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Doxorubicin—prostate cancer	3.63e-05	0.000244	CcSEcCtD
Dexrazoxane—Pruritus—Docetaxel—prostate cancer	3.62e-05	0.000243	CcSEcCtD
Dexrazoxane—Anaemia—Doxorubicin—prostate cancer	3.61e-05	0.000243	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Prednisone—prostate cancer	3.6e-05	0.000242	CcSEcCtD
Dexrazoxane—Myalgia—Epirubicin—prostate cancer	3.6e-05	0.000241	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.57e-05	0.00024	CcSEcCtD
Dexrazoxane—Discomfort—Epirubicin—prostate cancer	3.55e-05	0.000239	CcSEcCtD
Dexrazoxane—Asthenia—Capecitabine—prostate cancer	3.55e-05	0.000238	CcSEcCtD
Dexrazoxane—Malaise—Doxorubicin—prostate cancer	3.52e-05	0.000237	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CD82—prostate cancer	3.52e-05	0.0181	CbGpPWpGaD
Dexrazoxane—Dry mouth—Epirubicin—prostate cancer	3.52e-05	0.000236	CcSEcCtD
Dexrazoxane—Syncope—Doxorubicin—prostate cancer	3.5e-05	0.000235	CcSEcCtD
Dexrazoxane—Urticaria—Prednisone—prostate cancer	3.5e-05	0.000235	CcSEcCtD
Dexrazoxane—Pruritus—Capecitabine—prostate cancer	3.5e-05	0.000235	CcSEcCtD
Dexrazoxane—Leukopenia—Doxorubicin—prostate cancer	3.5e-05	0.000235	CcSEcCtD
Dexrazoxane—Diarrhoea—Docetaxel—prostate cancer	3.5e-05	0.000235	CcSEcCtD
Dexrazoxane—Body temperature increased—Prednisone—prostate cancer	3.48e-05	0.000234	CcSEcCtD
Dexrazoxane—Abdominal pain—Prednisone—prostate cancer	3.48e-05	0.000234	CcSEcCtD
Dexrazoxane—Loss of consciousness—Doxorubicin—prostate cancer	3.43e-05	0.000231	CcSEcCtD
Dexrazoxane—Infection—Epirubicin—prostate cancer	3.42e-05	0.00023	CcSEcCtD
Dexrazoxane—Cough—Doxorubicin—prostate cancer	3.41e-05	0.000229	CcSEcCtD
Dexrazoxane—Shock—Epirubicin—prostate cancer	3.39e-05	0.000228	CcSEcCtD
Dexrazoxane—Diarrhoea—Capecitabine—prostate cancer	3.38e-05	0.000227	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—ID3—prostate cancer	3.38e-05	0.0173	CbGpPWpGaD
Dexrazoxane—Nervous system disorder—Epirubicin—prostate cancer	3.38e-05	0.000227	CcSEcCtD
Dexrazoxane—Dizziness—Docetaxel—prostate cancer	3.38e-05	0.000227	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Epirubicin—prostate cancer	3.37e-05	0.000227	CcSEcCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—APC—prostate cancer	3.35e-05	0.0172	CbGpPWpGaD
Dexrazoxane—Skin disorder—Epirubicin—prostate cancer	3.35e-05	0.000225	CcSEcCtD
Dexrazoxane—Myalgia—Doxorubicin—prostate cancer	3.33e-05	0.000223	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.3e-05	0.000222	CcSEcCtD
Dexrazoxane—Discomfort—Doxorubicin—prostate cancer	3.29e-05	0.000221	CcSEcCtD
Dexrazoxane—Anorexia—Epirubicin—prostate cancer	3.29e-05	0.000221	CcSEcCtD
Dexrazoxane—Dizziness—Capecitabine—prostate cancer	3.27e-05	0.00022	CcSEcCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—prostate cancer	3.26e-05	0.0167	CbGpPWpGaD
Dexrazoxane—Dry mouth—Doxorubicin—prostate cancer	3.25e-05	0.000219	CcSEcCtD
Dexrazoxane—Vomiting—Docetaxel—prostate cancer	3.25e-05	0.000218	CcSEcCtD
Dexrazoxane—Headache—Docetaxel—prostate cancer	3.2e-05	0.000215	CcSEcCtD
Dexrazoxane—Infection—Doxorubicin—prostate cancer	3.17e-05	0.000213	CcSEcCtD
Dexrazoxane—Asthenia—Prednisone—prostate cancer	3.16e-05	0.000212	CcSEcCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—VDR—prostate cancer	3.15e-05	0.0162	CbGpPWpGaD
Dexrazoxane—Vomiting—Capecitabine—prostate cancer	3.15e-05	0.000211	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.14e-05	0.000211	CcSEcCtD
Dexrazoxane—Shock—Doxorubicin—prostate cancer	3.14e-05	0.000211	CcSEcCtD
Dexrazoxane—TOP2A—Methyltestosterone—Prednisone—prostate cancer	3.13e-05	0.00907	CbGdCrCtD
Dexrazoxane—Nervous system disorder—Doxorubicin—prostate cancer	3.13e-05	0.00021	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Doxorubicin—prostate cancer	3.12e-05	0.00021	CcSEcCtD
Dexrazoxane—Pruritus—Prednisone—prostate cancer	3.12e-05	0.000209	CcSEcCtD
Dexrazoxane—Insomnia—Epirubicin—prostate cancer	3.12e-05	0.000209	CcSEcCtD
Dexrazoxane—Headache—Capecitabine—prostate cancer	3.1e-05	0.000208	CcSEcCtD
Dexrazoxane—Skin disorder—Doxorubicin—prostate cancer	3.1e-05	0.000208	CcSEcCtD
Dexrazoxane—Dyspnoea—Epirubicin—prostate cancer	3.07e-05	0.000206	CcSEcCtD
Dexrazoxane—Somnolence—Epirubicin—prostate cancer	3.06e-05	0.000206	CcSEcCtD
Dexrazoxane—Anorexia—Doxorubicin—prostate cancer	3.04e-05	0.000204	CcSEcCtD
Dexrazoxane—Nausea—Docetaxel—prostate cancer	3.04e-05	0.000204	CcSEcCtD
Dexrazoxane—Diarrhoea—Prednisone—prostate cancer	3.02e-05	0.000203	CcSEcCtD
Dexrazoxane—Decreased appetite—Epirubicin—prostate cancer	3e-05	0.000201	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Epirubicin—prostate cancer	2.98e-05	0.0002	CcSEcCtD
Dexrazoxane—Fatigue—Epirubicin—prostate cancer	2.97e-05	0.0002	CcSEcCtD
Dexrazoxane—Constipation—Epirubicin—prostate cancer	2.95e-05	0.000198	CcSEcCtD
Dexrazoxane—Pain—Epirubicin—prostate cancer	2.95e-05	0.000198	CcSEcCtD
Dexrazoxane—Nausea—Capecitabine—prostate cancer	2.94e-05	0.000197	CcSEcCtD
Dexrazoxane—Dizziness—Prednisone—prostate cancer	2.91e-05	0.000196	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.91e-05	0.000195	CcSEcCtD
Dexrazoxane—Insomnia—Doxorubicin—prostate cancer	2.88e-05	0.000194	CcSEcCtD
Dexrazoxane—Dyspnoea—Doxorubicin—prostate cancer	2.84e-05	0.000191	CcSEcCtD
Dexrazoxane—Feeling abnormal—Epirubicin—prostate cancer	2.84e-05	0.000191	CcSEcCtD
Dexrazoxane—Somnolence—Doxorubicin—prostate cancer	2.84e-05	0.00019	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Epirubicin—prostate cancer	2.82e-05	0.000189	CcSEcCtD
Dexrazoxane—Vomiting—Prednisone—prostate cancer	2.8e-05	0.000188	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—DAG1—prostate cancer	2.8e-05	0.0143	CbGpPWpGaD
Dexrazoxane—Decreased appetite—Doxorubicin—prostate cancer	2.77e-05	0.000186	CcSEcCtD
Dexrazoxane—Headache—Prednisone—prostate cancer	2.76e-05	0.000185	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.75e-05	0.000185	CcSEcCtD
Dexrazoxane—Fatigue—Doxorubicin—prostate cancer	2.75e-05	0.000185	CcSEcCtD
Dexrazoxane—Urticaria—Epirubicin—prostate cancer	2.74e-05	0.000184	CcSEcCtD
Dexrazoxane—Pain—Doxorubicin—prostate cancer	2.73e-05	0.000183	CcSEcCtD
Dexrazoxane—Constipation—Doxorubicin—prostate cancer	2.73e-05	0.000183	CcSEcCtD
Dexrazoxane—Abdominal pain—Epirubicin—prostate cancer	2.72e-05	0.000183	CcSEcCtD
Dexrazoxane—Body temperature increased—Epirubicin—prostate cancer	2.72e-05	0.000183	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—DNMT1—prostate cancer	2.7e-05	0.0139	CbGpPWpGaD
Dexrazoxane—Feeling abnormal—Doxorubicin—prostate cancer	2.63e-05	0.000177	CcSEcCtD
Dexrazoxane—Nausea—Prednisone—prostate cancer	2.62e-05	0.000176	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Doxorubicin—prostate cancer	2.61e-05	0.000175	CcSEcCtD
Dexrazoxane—Urticaria—Doxorubicin—prostate cancer	2.53e-05	0.00017	CcSEcCtD
Dexrazoxane—Body temperature increased—Doxorubicin—prostate cancer	2.52e-05	0.000169	CcSEcCtD
Dexrazoxane—Abdominal pain—Doxorubicin—prostate cancer	2.52e-05	0.000169	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—STMN1—prostate cancer	2.51e-05	0.0129	CbGpPWpGaD
Dexrazoxane—Asthenia—Epirubicin—prostate cancer	2.47e-05	0.000166	CcSEcCtD
Dexrazoxane—Pruritus—Epirubicin—prostate cancer	2.44e-05	0.000164	CcSEcCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—ATM—prostate cancer	2.43e-05	0.0125	CbGpPWpGaD
Dexrazoxane—Diarrhoea—Epirubicin—prostate cancer	2.36e-05	0.000158	CcSEcCtD
Dexrazoxane—Asthenia—Doxorubicin—prostate cancer	2.29e-05	0.000154	CcSEcCtD
Dexrazoxane—Dizziness—Epirubicin—prostate cancer	2.28e-05	0.000153	CcSEcCtD
Dexrazoxane—Pruritus—Doxorubicin—prostate cancer	2.26e-05	0.000152	CcSEcCtD
Dexrazoxane—Vomiting—Epirubicin—prostate cancer	2.19e-05	0.000147	CcSEcCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—GSK3B—prostate cancer	2.19e-05	0.0112	CbGpPWpGaD
Dexrazoxane—Diarrhoea—Doxorubicin—prostate cancer	2.18e-05	0.000147	CcSEcCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—CTNNB1—prostate cancer	2.16e-05	0.0111	CbGpPWpGaD
Dexrazoxane—Headache—Epirubicin—prostate cancer	2.16e-05	0.000145	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—PSMC3IP—prostate cancer	2.11e-05	0.0108	CbGpPWpGaD
Dexrazoxane—Dizziness—Doxorubicin—prostate cancer	2.11e-05	0.000142	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—HNF1B—prostate cancer	2.09e-05	0.0107	CbGpPWpGaD
Dexrazoxane—Nausea—Epirubicin—prostate cancer	2.05e-05	0.000138	CcSEcCtD
Dexrazoxane—Vomiting—Doxorubicin—prostate cancer	2.03e-05	0.000136	CcSEcCtD
Dexrazoxane—Headache—Doxorubicin—prostate cancer	2e-05	0.000134	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—HSP90AB1—prostate cancer	1.98e-05	0.0101	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EIF2AK2—prostate cancer	1.9e-05	0.00975	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—prostate cancer	1.9e-05	0.00972	CbGpPWpGaD
Dexrazoxane—Nausea—Doxorubicin—prostate cancer	1.89e-05	0.000127	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—USO1—prostate cancer	1.89e-05	0.00967	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—PCNT—prostate cancer	1.89e-05	0.00967	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PRKDC—prostate cancer	1.86e-05	0.00955	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—prostate cancer	1.8e-05	0.00924	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—prostate cancer	1.79e-05	0.0092	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—REC8—prostate cancer	1.79e-05	0.00919	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—AHR—prostate cancer	1.78e-05	0.00911	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—MYC—prostate cancer	1.75e-05	0.00896	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—EGFR—prostate cancer	1.71e-05	0.00877	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—PCNT—prostate cancer	1.69e-05	0.00864	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—USO1—prostate cancer	1.69e-05	0.00864	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—prostate cancer	1.62e-05	0.00829	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—IGFBP3—prostate cancer	1.61e-05	0.00824	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ACHE—prostate cancer	1.57e-05	0.00804	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND2—prostate cancer	1.55e-05	0.00795	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TGFBR1—prostate cancer	1.53e-05	0.00786	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—THBS1—prostate cancer	1.46e-05	0.0075	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ANXA1—prostate cancer	1.44e-05	0.00739	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—TP53—prostate cancer	1.44e-05	0.00736	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EZH2—prostate cancer	1.4e-05	0.00716	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—GADD45A—prostate cancer	1.37e-05	0.00703	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—NCOA2—prostate cancer	1.36e-05	0.00696	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—EZH2—prostate cancer	1.34e-05	0.00687	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—TYMS—prostate cancer	1.33e-05	0.00684	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ESR2—prostate cancer	1.29e-05	0.00663	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—prostate cancer	1.25e-05	0.00643	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP9—prostate cancer	1.24e-05	0.00637	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TH—prostate cancer	1.23e-05	0.00632	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EGR1—prostate cancer	1.21e-05	0.00621	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA1—prostate cancer	1.18e-05	0.00602	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—EGR1—prostate cancer	1.16e-05	0.00596	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—NGFR—prostate cancer	1.16e-05	0.00592	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—AR—prostate cancer	1.14e-05	0.00586	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—RXRA—prostate cancer	1.13e-05	0.00581	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—prostate cancer	1.1e-05	0.00562	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA2—prostate cancer	1.06e-05	0.00545	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—SIRT1—prostate cancer	1.04e-05	0.00534	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—prostate cancer	1.01e-05	0.00518	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—prostate cancer	1e-05	0.00513	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—SIRT1—prostate cancer	1e-05	0.00513	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BAX—prostate cancer	9.74e-06	0.00499	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TYMS—prostate cancer	9.71e-06	0.00497	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—prostate cancer	9.55e-06	0.00489	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FASLG—prostate cancer	9.29e-06	0.00476	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—prostate cancer	9.24e-06	0.00473	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—HIST1H2BG—prostate cancer	9.04e-06	0.00463	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—HIST1H4H—prostate cancer	8.73e-06	0.00447	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PPARA—prostate cancer	8.32e-06	0.00426	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MAD1L1—prostate cancer	8.21e-06	0.00421	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—HIST1H2BG—prostate cancer	8.08e-06	0.00414	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—prostate cancer	7.92e-06	0.00406	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—LEP—prostate cancer	7.89e-06	0.00405	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—prostate cancer	7.85e-06	0.00402	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—HIST1H4H—prostate cancer	7.81e-06	0.004	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BAD—prostate cancer	7.66e-06	0.00393	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MYC—prostate cancer	7.66e-06	0.00393	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—APC—prostate cancer	7.42e-06	0.0038	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MAD1L1—prostate cancer	7.34e-06	0.00376	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EGF—prostate cancer	7.34e-06	0.00376	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN1B—prostate cancer	7.04e-06	0.00361	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—prostate cancer	6.88e-06	0.00353	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—GSK3B—prostate cancer	6.84e-06	0.0035	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—prostate cancer	6.79e-06	0.00348	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—AURKA—prostate cancer	6.79e-06	0.00348	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—NBN—prostate cancer	6.75e-06	0.00346	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND1—prostate cancer	6.72e-06	0.00344	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MLH1—prostate cancer	6.71e-06	0.00344	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAP2K1—prostate cancer	6.57e-06	0.00337	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN1A—prostate cancer	6.5e-06	0.00333	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TP53—prostate cancer	6.29e-06	0.00322	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FGF2—prostate cancer	6.25e-06	0.0032	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—SERPINE1—prostate cancer	6.19e-06	0.00317	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—AURKA—prostate cancer	6.07e-06	0.00311	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BCL2—prostate cancer	5.93e-06	0.00304	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—APEX1—prostate cancer	5.9e-06	0.00302	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—prostate cancer	5.84e-06	0.003	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—prostate cancer	5.76e-06	0.00295	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND2—prostate cancer	5.69e-06	0.00292	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—prostate cancer	5.63e-06	0.00289	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CHEK2—prostate cancer	5.43e-06	0.00278	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—MYC—prostate cancer	5.39e-06	0.00276	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—prostate cancer	5.34e-06	0.00274	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—APEX1—prostate cancer	5.27e-06	0.0027	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—prostate cancer	5.23e-06	0.00268	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—prostate cancer	5.09e-06	0.00261	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—BRCA1—prostate cancer	5.09e-06	0.00261	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCND2—prostate cancer	5.09e-06	0.00261	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—prostate cancer	5.04e-06	0.00258	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—prostate cancer	4.92e-06	0.00252	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—prostate cancer	4.91e-06	0.00252	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—TYMS—prostate cancer	4.89e-06	0.00251	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PTEN—prostate cancer	4.72e-06	0.00242	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—prostate cancer	4.69e-06	0.0024	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—BRCA2—prostate cancer	4.6e-06	0.00236	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—prostate cancer	4.56e-06	0.00234	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—EP300—prostate cancer	4.5e-06	0.00231	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—prostate cancer	4.44e-06	0.00227	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TYMS—prostate cancer	4.38e-06	0.00224	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—prostate cancer	4.08e-06	0.00209	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—prostate cancer	4.07e-06	0.00209	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	3.99e-06	0.00205	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TERT—prostate cancer	3.81e-06	0.00195	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	3.77e-06	0.00193	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	3.47e-06	0.00178	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—ATM—prostate cancer	3.43e-06	0.00176	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	3.35e-06	0.00172	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TP53—prostate cancer	3.22e-06	0.00165	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—IL6—prostate cancer	2.95e-06	0.00151	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	2.83e-06	0.00145	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN1B—prostate cancer	2.58e-06	0.00132	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MDM2—prostate cancer	2.53e-06	0.0013	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND1—prostate cancer	2.46e-06	0.00126	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN1A—prostate cancer	2.38e-06	0.00122	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN1B—prostate cancer	2.31e-06	0.00118	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—EP300—prostate cancer	2.27e-06	0.00116	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCND1—prostate cancer	2.2e-06	0.00113	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN1A—prostate cancer	2.13e-06	0.00109	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—EP300—prostate cancer	2.03e-06	0.00104	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MYC—prostate cancer	1.98e-06	0.00101	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MYC—prostate cancer	1.77e-06	0.000906	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TP53—prostate cancer	1.45e-06	0.000744	CbGpPWpGaD
